Eurofins-Cerep (XPAR:ALECR) Debt-to-Equity : 0.01 (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Eurofins-Cerep Debt-to-Equity?

Eurofins-Cerep's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Eurofins-Cerep's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.32 Mil. Eurofins-Cerep's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €67.43 Mil. Eurofins-Cerep's debt to equity for the quarter that ended in Jun. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eurofins-Cerep's Debt-to-Equity or its related term are showing as below:

XPAR:ALECR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.01
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Eurofins-Cerep was 0.01. The lowest was 0.00. And the median was 0.01.

XPAR:ALECR's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.275 vs XPAR:ALECR: 0.01

Eurofins-Cerep Debt-to-Equity Historical Data

The historical data trend for Eurofins-Cerep's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eurofins-Cerep Debt-to-Equity Chart

Eurofins-Cerep Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

Eurofins-Cerep Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	0.01

Competitive Comparison of Eurofins-Cerep's Debt-to-Equity

For the Diagnostics & Research subindustry, Eurofins-Cerep's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eurofins-Cerep's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eurofins-Cerep's Debt-to-Equity falls into.

Eurofins-Cerep Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eurofins-Cerep's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.003)	/	64.615
	=	0.00

Eurofins-Cerep's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.317)	/	67.428
	=	0.00

Eurofins-Cerep (XPAR:ALECR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eurofins-Cerep Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eurofins-Cerep's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eurofins-Cerep Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Eurofins-Cerep SA (XPAR:ALECR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Le bois l Eveque, Celle l Evescault, FRA, 86600

Website

http://www.cerep.fr

Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.

Eurofins-Cerep Headlines

No Headlines